Lyra Therapeutics Long Term Debt

Lyra Therapeutics (LYRA) currently reports a long-term debt of $25M as of December 2025. That compares with $30M in the prior-year period — down 15.9% year over year. Use the charts on this page to explore Lyra Therapeutics's long-term debt history and peer comparisons.

Lyra Therapeutics's long-term debt decreased from $30M to $25M — a 15.9% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lyra Therapeutics reported $25M in long-term debt as of December 2025. That compares with $30M in the prior-year period — down 15.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.

Lyra Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYRA with unrelated industries.